Skip to main content

Progenity Acquires Medimetrics' Patent Portfolio

NEW YORK –Progenity announced today it has acquired Medimetrics' patent portfolio for ingestible device technologies.

Financial terms of the agreement were not disclosed.

Medimetrics, based in the Netherlands, is an ingestible device company with 137 granted patents and 15 pending patent applications in the US, Europe, China, and Japan.

Following the purchase, San Diego-based Progenity will own 200 granted patents and 216 pending applications.

Its intellectual property portfolio now includes technologies in autonomous self-localization, sample collection and preservation from preselected gastrointestinal locations, and targeted therapeutic delivery to the GI tract. In April, the company launched a prenatal testing service for the noninvasive detection of monogenic disorders.

Progenity said in a statement that its ingestible technologies can help diagnose and treat GI diseases, such as inflammatory bowel disease, with minimal invasion and cost. The company is currently developing technologies that can wirelessly send data to clinicians while traveling in the GI tract and deliver therapies directly to the intestines.

“Medimetrics’ expertise in device development and system engineering set the stage for ingestible drug delivery and sampling, even garnering CE marks for several products for clinical and commercial use,” said Jeff Shimizu, director of device development at Progenity.